What is claimed is:

1. An isolated nucleic acid which comprises a sequence encoding an isolated anti-Epidermal Growth Factor Receptor (EGFR) antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166.

2. A method of preparing an isolated anti-Epidermal Growth Factor Receptor (EGFR) monoclonal IgG antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, wherein the antibody is characterized by a single binding affinity for an antigen, comprising expressing a nucleic acid under conditions to bring about expression of said antibody, and recovering said antibody.

3. A kit for the diagnosis of a tumor in which EGFR is aberrantly expressed or EGFR is expressed in the form of a truncated protein, comprising an isolated anti-Epidermal Growth Factor Receptor (EGFR) monoclonal IgG antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, wherein the antibody is characterized by a single binding affinity for an antigen, further comprising reagents and/or instructions for use.

4. A unicellular host transformed with a recombinant DNA molecule which encodes an isolated anti-Epidermal Growth Factor Receptor (EGFR) monoclonal IgG antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, wherein the antibody is characterized by a single binding affinity for an antigen.

5. An immunoconjugate comprising an isolated anti-Epidermal Growth Factor Receptor (EGFR) monoclonal IgG antibody conjugated to a cytotoxic agent, wherein said antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, wherein the antibody is characterized by a single binding affinity for an antigen.

6. The immunoconjugate of claim 5, wherein said antibody comprises a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 48.

7. The immunoconjugate of claim 5, wherein said antibody is an IgG1 isotype.

8. A pharmaceutical composition comprising the immunoconjugate according to claim 5.

9. The immunoconjugate of claim 5, wherein said antibody comprises a kappa light chain.

10. The isolated antibody of claim 1, wherein said antibody comprises a kappa light chain.

~~11. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 190.~~

~~12. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 41.~~

~~13. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 192.~~

~~14. The isolated nucleic acid of claim 13, wherein the nucleic acid further comprises a nucleotide sequence encoding an antibody heavy chain constant region.~~

~~15. The isolated nucleic acid of claim 14, wherein the antibody heavy chain constant region is an IgG1 constant region.~~

~~16. A recombinant expression vector comprising the nucleic acid of any one of claims 1 or 11 to 15.~~

~~17. A host cell comprising the recombinant expression vector of claim 16.~~

~~18. The host cell of claim 17, wherein the host cell is selected from the group consisting of E. coli, Pseudomonas, Bacillus, Streptomyces, yeasts, a mammalian cell, a plant cell, and an insect cell.~~

~~19. The host cell of claim 18, wherein the mammalian cell is selected from the group consisting of CHO, YB/20, NSO, SP2/0, R1.1, B-W, L-M,. COS1, COS7, BSC1, BSC40, and BMT10 cells, and a human cell.~~

~~20. A method of synthesizing an antibody that binds EGFR comprising culturing the host cell of claim 17 in a culture medium,~~
~~allowing expression from the nucleic acid, and~~
~~recovering the antibody.~~